Log in
Login
Password
Remember
Lost password
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Shares  >  Euronext Bruxelles  >  ABLYNX    ABLX   BE0003877942

ABLYNX (ABLX)

359
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

ABLYNX (D) : ANNOUNCES WEBCAST OF ITS PRESENTATION AT THE 29TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

01/04/2011 | 12:10pm US/Eastern

GHENT, Belgium, 4 January 2011 - Ablynx [Euronext Brussels: ABLX] today announced that it will webcast its corporate presentation at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, 11 January 2011 at 11.00 a.m. PST / 08.00 p.m. CET.

 

The presentation, followed by a Q&A, will be hosted by Dr Edwin Moses, CEO and Chairman of Ablynx. The presentation will be webcast live and may be accessed on the home page of Ablynx's website at www.ablynx.com:
http://www.ablynx.com/. A replay of the webcast will also be available on the Company's website for 30 days following the presentation.

 

To ensure a timely connection, it is recommended that users register at least 10 minutes prior to the scheduled webcast.

 

 

About Ablynx

Ablynx:
http://www.ablynx.com/ (Euronext: ABLX) is a biopharmaceutical company engaged in the discovery and development of Nanobodies®:
http://www.ablynx.com/en/research-development/nanobody-technology/understanding-nanobodies/, a novel class of therapeutic proteins based on single-domain antibody fragments, for a range of serious and life-threatening human diseases, including inflammation, thrombosis, oncology and Alzheimer's disease. Today, the Company has over 25 projects in the pipeline:
http://www.ablynx.com/en/research-development/pipeline/ and there are five Nanobodies in clinical development. In parallel with its internally developed products, Ablynx has ongoing research collaborations and significant partnerships with major pharmaceutical companies, including Boehringer Ingelheim, Merck Serono, Novartis and Pfizer. The Company is headquartered in Ghent, Belgium and currently employs over 250 people. More information can be found on www.ablynx.com:
http://www.ablynx.com/.

 

 

For more information, please contact Ablynx:

Dr Edwin Moses
Chairman and CEO
t:   +32 (0)9 262 00 07
m: +44 (0)7771 954 193 /
     +32 (0)473 39 50 68

e:  edwin.moses@ablynx.com:
mailto:edwin.moses@ablynx.com

 

Marieke Vermeersch
Investor Relations Manager
t:   +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e:  marieke.vermeersch@ablynx.com :
mailto:marieke.vermeersch@ablynx.com%20

 

Complete version of the press release:
http://hugin.info/137912/R/1477060/413118.pdf

This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: Ablynx via Thomson Reuters ONE


HUG#1477060


React to this article
Latest news on ABLYNX
07/01 ABLYNX : 01/07/2015 taube hodson stonex partners llp announce 5.14% shareholding..
07/01 ABLYNX : Taube hodson stonex partners llp announce 5.14% shareholding in ablynx
06/30 ABLYNX : 30/06/2015 ABLYNX AND TAISHO SIGN EXCLUSIVE LICENSE AGREEMENT FOR THE D..
06/30 ABLYNX : AND TAISHO SIGN EXCLUSIVE LICENSE AGREEMENT FOR THE DEVELOPMENT AND COM..
06/17 ABLYNX : 17/06/2015 ablynx announces presentations on its potential first-in-cla..
06/17 ABLYNX : Announces presentations on its potential first-in-class treatment for a..
06/05 ABLYNX : Announces warrant exercise
05/28 ABLYNX : 28/05/2015 ablynx to present at the annual jefferies 2015 global health..
05/28 ABLYNX : To present at the annual jefferies 2015 global healthcare conference
05/26 ABLYNX : 26/05/2015 fmr llc announce 5.07% shareholding in ablynx
Advertisement
Chart
Duration : Period :
ABLYNX Technical Analysis Chart | ABLX | BE0003877942 | 4-Traders
Income Statement Evolution
More Financials